DarioHealth Corp., a digital health company, develops and commercializes patented and proprietary technologies providing consumers with laboratory-testing capabilities using smart phones and other mobile devices in the United States, Europe, Australia, and Canada. The company's flagship product, Dario, also known as Dario Smart Diabetes Management Solution, is a mobile, real-time, cloud-based, diabetes management solution based on a software application combined with Dario Smart Meter, a pocket-sized, blood glucose monitoring device. It offers Dario Engage software platform, where the company digitally engages with Dario users and assists them in monitoring their chronic illnesses, as well as provides them with coaching, support, digital communications, and real time alerts, trends, and pattern analysis. DarioHealth Corp. markets its products directly to consumer cash sales, as well as retail pharmacy and distributors; and through e-stores. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was founded in 2011 and is headquartered in Caesarea, Israel.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:DRIO
CUSIPN/A
Phone972-4770-4055
Debt
Debt-to-Equity RatioN/A
Current Ratio1.84
Quick Ratio1.55
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$5.17 million
Price / Sales4.29
Cash FlowN/A
Price / CashN/A
Book Value$0.28 per share
Price / Book3.71
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$-15,740,000.00
Net Margins-353.28%
Return on Equity-443.39%
Return on Assets-279.08%
Miscellaneous
Employees48
Outstanding Shares21,340,000
Market Cap$26.04 million
DarioHealth (NASDAQ:DRIO) Frequently Asked Questions
What is DarioHealth's stock symbol?
DarioHealth trades on the NASDAQ under the ticker symbol "DRIO."
How were DarioHealth's earnings last quarter?
DarioHealth Corp (NASDAQ:DRIO) released its quarterly earnings data on Thursday, August, 9th. The company reported ($0.32) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.18) by $0.14. The firm had revenue of $2.06 million for the quarter. DarioHealth had a negative net margin of 353.28% and a negative return on equity of 443.39%. View DarioHealth's Earnings History.
When is DarioHealth's next earnings date?
What price target have analysts set for DRIO?
2 analysts have issued twelve-month target prices for DarioHealth's stock. Their predictions range from $3.50 to $3.50. On average, they expect DarioHealth's share price to reach $3.50 in the next twelve months. This suggests a possible upside of 236.5% from the stock's current price. View Analyst Price Targets for DarioHealth.
What is the consensus analysts' recommendation for DarioHealth?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DarioHealth in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for DarioHealth.
Who are some of DarioHealth's key competitors?
Some companies that are related to DarioHealth include Sensus Healthcare (SRTS), Motus GI (MOTS), Invuity (IVTY), CAS Medical Systems (CASM), Invo Bioscience (IVOB), Neovasc (NVCN), Arch Therapeutics (ARTH), Spectral Medical (EDTXF), Repro-Med Systems (REPR), SANUWAVE Health, Inc. Common Stock (SNWV), iCAD (ICAD), Restoration Robotics (HAIR), Nephros (NEPH), Valeritas (VLRX) and Presbia (LENS).
Who are DarioHealth's key executives?
DarioHealth's management team includes the folowing people:
- Mr. Erez Raphael, CEO, Pres & Director (Age 45)
- Mr. Zvi Ben David CPA, CFO, Treasurer & Sec. (Age 57)
- Ms. Joao Mendes-Roter, VP of Marketing
- Mr. Jean Christophe Muyl, Head of Commercialization North America
- Shmuel Herschberg, Marketing Director
Has DarioHealth been receiving favorable news coverage?
News articles about DRIO stock have been trending somewhat positive on Monday, Accern Sentiment reports. Accern identifies positive and negative news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. DarioHealth earned a daily sentiment score of 0.12 on Accern's scale. They also assigned news headlines about the company an impact score of 44.70 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next several days. View Recent Headlines for DarioHealth.
How do I buy shares of DarioHealth?
Shares of DRIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is DarioHealth's stock price today?
One share of DRIO stock can currently be purchased for approximately $1.04.
How big of a company is DarioHealth?
DarioHealth has a market capitalization of $26.04 million and generates $5.17 million in revenue each year. DarioHealth employs 48 workers across the globe.
How can I contact DarioHealth?
DarioHealth's mailing address is 8 HaToKhen Street, Caesarea Industrial Park L3, 3088900. The company can be reached via phone at 972-4770-4055 or via email at [email protected]
MarketBeat Community Rating for DarioHealth (NASDAQ DRIO)
MarketBeat's community ratings are surveys of what our community members think about DarioHealth and other stocks. Vote "Outperform" if you believe DRIO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DRIO will underperform the S&P 500 over the long term. You may vote once every thirty days.
